Evidence map›Paper›PMID 25378488›Full record

ArticleJournal of virology2015

Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.

Katie J Doores, Leopold Kong, Stefanie A Krumm, Khoa M Le, Devin Sok, Uri Laserson, Fernando Garces, Pascal Poignard, Ian A Wilson, Dennis R Burton

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 93 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Katie J DooresDepartment of Infectious Diseases, King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, United Kingdom katie.doores@kcl.ac.uk burton@scripps.edu.
Leopold KongIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
Stefanie A KrummDepartment of Infectious Diseases, King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, United Kingdom.
Khoa M LeDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA.
Devin SokDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA International AIDS Vaccine Initiative, New York, New York, USA.
Uri LasersonDepartment of Genetics, Harvard Medical School, Boston, Massachusetts, USA Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts, USA.
Fernando GarcesIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
Pascal PoignardDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA.
Ian A WilsonIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
Dennis R BurtonDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, USA Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, California, USA katie.doores@kcl.ac.uk burton@scripps.edu.
Scripps Research Institute · USInternational AIDS Vaccine Initiative · USGuy's Hospital · GBHarvard University · USKing's College London · GB

Funding

Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5M
Training Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8M
Viral correlates of neutralizing antibody responseU19AI090970 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI POIGNARD, PASCAL · 2010 to 2014
$9.3M
HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONINGR01AI033292 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 1992 to 2013
$5.9M
Structural Biology of HIV-1 Neutralizing Antibody Targets for Vaccine DesignR01AI084817 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WILSON, IAN A · 2009 to 2013
$3.2M
Structure and dynamics of native HIV-1 envelope trimersR56AI084817 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WILSON, IAN A · 2015 to 2015
$593k
Medical Research Council MR/K024426/1NHGRI NIH HHS T32 HG002295NIAID NIH HHS 1U19AI090970NIAID NIH HHS AI84817NIAID NIH HHS R01 AI033292NIAID NIH HHS R01 AI084817NIAID NIH HHS R56 AI084817NIAID NIH HHS U19 AI090970NIAID NIH HHS UM1 AI100663
6 · The paper itself

Abstract

unlabelledThe high-mannose patch of human immunodeficiency virus (HIV) envelope (Env) elicits broadly neutralizing antibodies (bnAbs) during natural infection relatively frequently, and consequently, this region has become a major target of vaccine design. However, it has also become clear that antibody recognition of the region is complex due, at least in part, to variability in neighboring loops and glycans critical to the epitopes. bnAbs against this region have some shared features and some distinguishing features that are crucial to understand in order to design optimal immunogens that can induce different classes of bnAbs against this region. Here, we compare two branches of a single antibody lineage, in which all members recognize the high-mannose patch. One branch (prototype bnAb PGT128) has a 6-amino-acid insertion in CDRH2 that is crucial for broad neutralization. Antibodies in this branch appear to favor a glycan site at N332 on gp120, and somatic hypermutation is required to accommodate the neighboring V1 loop glycans and glycan heterogeneity. The other branch (prototype bnAb PGT130) lacks the CDRH2 insertion. Antibodies in this branch are noticeably effective at neutralizing viruses with an alternate N334 glycan site but are less able to accommodate glycan heterogeneity. We identify a new somatic variant within this branch that is predominantly dependent on N334. The crystal structure of PGT130 offers insight into differences from PGT128. We conclude that different immunogens may be required to elicit bnAbs that have the optimal characteristics of the two branches of the lineage described. IMPORTANCE: Development of an HIV vaccine is of vital importance for prevention of new infections, and it is thought that elicitation of HIV bnAbs will be an important component of an effective vaccine. Increasingly, bnAbs that bind to the cluster of high-mannose glycans on the HIV envelope glycoprotein, gp120, are being highlighted as important templates for vaccine design. In particular, bnAbs from IAVI donor 36 (PGT125 to PGT131) have been shown to be extremely broad and potent. Combination of these bnAbs enhanced neutralization breadth considerably, suggesting that an optimal immunogen should elicit several antibodies from this family. Here we study the evolution of this antibody family to inform immunogen design. We identify two classes of bnAbs that differ in their recognition of the high-mannose patch and show that different immunogens may be required to elicit these different classes.

Indexed as

Amino Acid SequenceAntibodies, NeutralizingCrystallography, X-Rayenv Gene Products, Human Immunodeficiency VirusEpitopesHIVHIV AntibodiesHumansModels, MolecularProtein ConformationAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV Antibodies

Identifiers

PMID25378488
PMCPMC4300629
OpenAlexW2112310185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.